BURCON NUTRASCIENCE CORP (BU.CA) Fundamental Analysis & Valuation
TSX:BU • CA1208313009
2.5 CAD
+0.21 (+9.17%)
Last: Mar 4, 2026, 07:00 PM
This BU.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
We assign a fundamental rating of 2 out of 10 to BU. BU was compared to 29 industry peers in the Chemicals industry. Both the profitability and financial health of BU have multiple concerns. BU is valued quite expensive, but it does show an excellent growth.
1. BU.CA Profitability Analysis
1.1 Basic Checks
- In the past year BU has reported negative net income.
- In the past year BU has reported a negative cash flow from operations.
- In the past 5 years BU always reported negative net income.
- BU had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- BU has a worse Return On Assets (-53.81%) than 72.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.81% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. BU.CA Health Analysis
2.1 Basic Checks
- BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
- BU has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BU has been increased compared to 5 years ago.
- BU has a worse debt/assets ratio than last year.
2.2 Solvency
- BU has an Altman-Z score of -9.80. This is a bad value and indicates that BU is not financially healthy and even has some risk of bankruptcy.
- BU has a worse Altman-Z score (-9.80) than 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.8 |
ROIC/WACCN/A
WACC10.37%
2.3 Liquidity
- A Current Ratio of 0.22 indicates that BU may have some problems paying its short term obligations.
- The Current ratio of BU (0.22) is worse than 75.86% of its industry peers.
- BU has a Quick Ratio of 0.22. This is a bad value and indicates that BU is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of BU (0.15) is worse than 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.15 |
3. BU.CA Growth Analysis
3.1 Past
- BU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -89.90%.
- Looking at the last year, BU shows a very strong growth in Revenue. The Revenue has grown by 337.48%.
- Measured over the past years, BU shows a very strong growth in Revenue. The Revenue has been growing by 66.28% on average per year.
EPS 1Y (TTM)-89.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)337.48%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%1131.83%
3.2 Future
- Based on estimates for the next years, BU will show a very strong growth in Earnings Per Share. The EPS will grow by 224.01% on average per year.
- The Revenue is expected to grow by 228.16% on average over the next years. This is a very strong growth
EPS Next Y-803.01%
EPS Next 2Y224.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year146.15%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. BU.CA Valuation Analysis
4.1 Price/Earnings Ratio
- BU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- BU is valuated cheaply with a Price/Forward Earnings ratio of 0.38.
- Based on the Price/Forward Earnings ratio, BU is valued cheaper than 100.00% of the companies in the same industry.
- BU is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.11, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0.38 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- BU's earnings are expected to grow with 224.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y224.01%
EPS Next 3YN/A
5. BU.CA Dividend Analysis
5.1 Amount
- BU does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BU.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:BU (3/4/2026, 7:00:00 PM)
2.5
+0.21 (+9.17%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-11 2026-02-11/amc
Earnings (Next)06-22 2026-06-22/amc
Inst Owners5.83%
Inst Owner ChangeN/A
Ins Owners31.02%
Ins Owner ChangeN/A
Market Cap31.73M
Revenue(TTM)1.48M
Net Income(TTM)-12.90M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-511.65%
Min EPS beat(2)-579.61%
Max EPS beat(2)-443.69%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-29.44%
Min Revenue beat(2)-30.64%
Max Revenue beat(2)-28.24%
Revenue beat(4)1
Avg Revenue beat(4)-22.06%
Min Revenue beat(4)-95.36%
Max Revenue beat(4)66.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)100%
EPS NQ rev (3m)100%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-3.03%
Revenue NY rev (3m)-3.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0.38 | ||
| P/S | 21.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.06
EYN/A
EPS(NY)6.58
Fwd EY263.27%
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.12
BVpS-0.2
TBVpS-0.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.81% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 54.43% | ||
| Cap/Sales | 59.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.15 | ||
| Altman-Z | -9.8 |
F-Score5
WACC10.37%
ROIC/WACCN/A
Cap/Depr(3y)68.17%
Cap/Depr(5y)195.49%
Cap/Sales(3y)82.83%
Cap/Sales(5y)124.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-89.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-803.01%
EPS Next 2Y224.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)337.48%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%1131.83%
Revenue Next Year146.15%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-56.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.13%
OCF growth 3YN/A
OCF growth 5YN/A
BURCON NUTRASCIENCE CORP / BU.CA FAQ
What is the fundamental rating for BU stock?
ChartMill assigns a fundamental rating of 2 / 10 to BU.CA.
What is the valuation status for BU stock?
ChartMill assigns a valuation rating of 3 / 10 to BURCON NUTRASCIENCE CORP (BU.CA). This can be considered as Overvalued.
What is the profitability of BU stock?
BURCON NUTRASCIENCE CORP (BU.CA) has a profitability rating of 0 / 10.
What is the expected EPS growth for BURCON NUTRASCIENCE CORP (BU.CA) stock?
The Earnings per Share (EPS) of BURCON NUTRASCIENCE CORP (BU.CA) is expected to decline by -803.01% in the next year.